Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 11.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 572,834 shares of the company’s stock after buying an additional 61,114 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.75% of Nurix Therapeutics worth $10,792,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of NRIX. US Bancorp DE raised its holdings in shares of Nurix Therapeutics by 144.7% in the 4th quarter. US Bancorp DE now owns 1,424 shares of the company’s stock valued at $27,000 after buying an additional 842 shares during the period. Quarry LP raised its holdings in shares of Nurix Therapeutics by 3,746.2% in the 3rd quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $56,000 after buying an additional 2,435 shares during the period. Quest Partners LLC raised its holdings in shares of Nurix Therapeutics by 21.3% in the 3rd quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock valued at $168,000 after buying an additional 1,312 shares during the period. Bellevue Group AG purchased a new stake in Nurix Therapeutics during the 3rd quarter worth about $180,000. Finally, EP Wealth Advisors LLC purchased a new stake in Nurix Therapeutics during the 3rd quarter worth about $240,000.

Insiders Place Their Bets

In other news, CFO Houte Hans Van sold 5,825 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $14.49, for a total transaction of $84,404.25. Following the completion of the transaction, the chief financial officer now directly owns 33,724 shares of the company’s stock, valued at approximately $488,660.76. This represents a 14.73 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Gwenn Hansen sold 3,690 shares of the stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the transaction, the insider now directly owns 55,937 shares of the company’s stock, valued at approximately $1,110,349.45. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 12,326 shares of company stock valued at $213,449. 7.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Needham & Company LLC cut their price target on Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday, January 29th. JPMorgan Chase & Co. cut their price target on Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Morgan Stanley upped their price target on Nurix Therapeutics from $16.00 to $17.00 and gave the stock an “equal weight” rating in a report on Monday, February 3rd. BMO Capital Markets assumed coverage on Nurix Therapeutics in a report on Friday, December 6th. They set an “outperform” rating and a $35.00 price target on the stock. Finally, Stephens restated an “overweight” rating and set a $31.00 price target on shares of Nurix Therapeutics in a report on Tuesday, January 21st. Three investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $30.88.

Nurix Therapeutics Stock Down 6.3 %

Shares of NASDAQ NRIX opened at $12.99 on Friday. The stock has a market cap of $985.77 million, a PE ratio of -4.49 and a beta of 2.18. Nurix Therapeutics, Inc. has a 52-week low of $11.90 and a 52-week high of $29.56. The business has a 50-day moving average price of $17.00 and a 200 day moving average price of $20.77.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. Sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.